<unk>  is difficult to treat, most patients receive treatment based on the morphology of blasts and get AML or ALL induction chemotherapy. The induction drug for AML such as cytarabine and anthracycline, drug for ALL such as prednisolone, dexamethasone, vincristine, asparaginase or daunorubicin is common for<unk>  remission induction therapy. Recently, researches showed that using both myeloid and lymphoid induction therapy may be better for prognosis. Chemotherapy has strong side effects such as typhlitis, gastrointestinal distress, anemia, fatigue, hair loss, nausea and vomiting, etc. Thus, the different dose and times of chemotherapy for different individuals is important. If the patients enter fully remission, the consolidation with stem cell transplantation is highly recommended.
Biphenotypic acute leukaemia
Aggressive NK-cell leukemia
Mixed-phenotype acute leukemia
Leukemoid reaction
Atypical chronic myeloid leukemia
Prolymphocytic leukemia
T-cell prolymphocytic leukemia
B-cell prolymphocytic leukemia